Sustained Acid Suppression by Potassium-Competitive Acid Blocker (P-CAB) May Be An Attractive Treatment Candidate for Patients with Eosinophilic Esophagitis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Eosinophilic Esophagitis: Mechanisms of Disease and Approach to Treatment.Current allergy and asthma reports · 2026
   Review
2. Long-term Outcome of Asymptomatic Esophageal Eosinophilia.Gut and liver · 2024
   Article
3. Eosinophilic Gastrointestinal Diseases: The Pathogenesis, Diagnosis, and Treatment.Internal medicine (Tokyo, Japan) · 2023
   Article
4. Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders.Gastroenterology & hepatology · 2022
   Article
5. The Impact of Duodenal Mucosal Vulnerability in the Development of Epigastric Pain Syndrome in Functional Dyspepsia.International journal of molecular sciences · 2022
   Article
6. Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis.Esophagus : official journal of the Japan Esophageal Society · 2021
   Article
7. Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults.Therapeutic advances in gastroenterology · 2021
   Review
8. Symptom-based diagnostic approach for eosinophilic esophagitis.Journal of gastroenterology · 2020
   Review
9. Clinical Manifestations of Eosinophilic Esophagitis in Children and Adolescents: A Single-Center, Matched Case-Control Study.Pediatric gastroenterology, hepatology & nutrition · 2020
   Article
10. Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review.Drugs · 2019
    Review
11. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.Therapeutic advances in gastroenterology · 2018
    Review
12. The Role of Proton Pump Inhibitors in the Management of Pediatric Eosinophilic Esophagitis.Frontiers in pediatrics · 2018
    Review
13. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: A Paradigm Shift.The American journal of gastroenterology · 2017
    Article
14. Management of refractory eosinophilic oesophagitis.Nature reviews. Gastroenterology & hepatology · 2017
    Review
15. Recent advances in eosinophilic esophagitis.F1000Research · 2017
    Review
16. Response to Ishimura et al.The American journal of gastroenterology · 2016
    Article
17. [Therapeutic Developments in Eosinophilic Esophagitis].Acta gastroenterologica Latinoamericana
    Review
18. [Diagnosis and Treatment of Eosinophilic Esophagitis].Acta gastroenterologica Latinoamericana
    Review

Corrections and comments

• Commented on by
  Response to Ishimura et al.2016
• Comment on
  Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis.2015

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as